187 related articles for article (PubMed ID: 29771164)
41. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
42. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
43. Physical symptom profile for adult cancer inpatients at a Lebanese cancer unit.
Halawi R; Aldin ES; Baydoun A; Dbouk H; Nahleh Z; Nasser Z; Tfayli A
Eur J Intern Med; 2012 Dec; 23(8):e185-9. PubMed ID: 23009863
[TBL] [Abstract][Full Text] [Related]
44. Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation.
Nielsen TK; Højgaard M; Andersen JT; Poulsen HE; Lykkesfeldt J; Mikines KJ
Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):343-8. PubMed ID: 25220574
[TBL] [Abstract][Full Text] [Related]
45. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
46. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
47. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients.
Mikirova N; Casciari J; Riordan N; Hunninghake R
J Transl Med; 2013 Aug; 11():191. PubMed ID: 23947403
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
49. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review.
van Gorkom GNY; Lookermans EL; Van Elssen CHMJ; Bos GMJ
Nutrients; 2019 Apr; 11(5):. PubMed ID: 31035414
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy and safety of two methods of administration of granisetron injection for nausea and vomiting induced by chemotherapy for tumors in hematopoietic organs--a randomized crossover comparison between intravenous drip infusion and intravenous bolus injection].
Tsudo M; Moriguchi T
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1747-53. PubMed ID: 9757201
[TBL] [Abstract][Full Text] [Related]
51. MS-20, a chemotherapeutical adjuvant, reduces chemo-associated fatigue and appetite loss in cancer patients.
Chi KH; Chiou TJ; Li CP; Chen SY; Chao Y
Nutr Cancer; 2014; 66(7):1211-9. PubMed ID: 25256137
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
[TBL] [Abstract][Full Text] [Related]
53. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.
Riordan HD; Riordan NH; Jackson JA; Casciari JJ; Hunninghake R; González MJ; Mora EM; Miranda-Massari JR; Rosario N; Rivera A
P R Health Sci J; 2004 Jun; 23(2):115-8. PubMed ID: 15377059
[TBL] [Abstract][Full Text] [Related]
54. Clinical trial of adverse effect inhibition with glucosides of vitamin C and vitamin E in radiotherapy and chemotherapy.
Koizumi M; Nishimura T; Kagiya T
J Cancer Res Ther; 2005; 1(4):239. PubMed ID: 17998662
[No Abstract] [Full Text] [Related]
55. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
[TBL] [Abstract][Full Text] [Related]
56. Orange juice intake reduces patient discomfort and is effective for bowel cleansing with polyethylene glycol during bowel preparation.
Choi HS; Shim CS; Kim GW; Kim JS; Lee SY; Sung IK; Park HS; Kim JH
Dis Colon Rectum; 2014 Oct; 57(10):1220-7. PubMed ID: 25203380
[TBL] [Abstract][Full Text] [Related]
57. The shortened infusion time of intravenous ibuprofen, part 2: a multicenter, open-label, surgical surveillance trial to evaluate safety.
Gan TJ; Candiotti K; Turan A; Buvanendran A; Philip BK; Viscusi ER; Soghomonyan S; Bergese SD;
Clin Ther; 2015 Feb; 37(2):368-75. PubMed ID: 25592331
[TBL] [Abstract][Full Text] [Related]
58. Understanding the concept of chemotherapy-related nausea: the patient experience.
Molassiotis A; Stricker CT; Eaby B; Velders L; Coventry PA
Eur J Cancer Care (Engl); 2008 Sep; 17(5):444-53. PubMed ID: 18637116
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
60. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
